Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation

Carfilzomib (CFZ) is the second-in-class proteasome inhibitor with much improved efficacy and safety profiles over bortezomib in multiple myeloma patients. In expanding the utility of CFZ to solid cancer therapy, the poor aqueous solubility and in vivo instability of CFZ are considered major drawbac...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of controlled release 2019-05, Vol.302, p.148-159
Hauptverfasser:	Park, Ji Eun, Park, Joonyoung, Jun, Yearin, Oh, Yunseok, Ryoo, Gongmi, Jeong, Yoo-Seong, Gadalla, Hytham H, Min, Jee Sun, Jo, Jung Hwan, Song, Myung Geun, Kang, Keon Wook, Bae, Soo Kyung, Yeo, Yoon, Lee, Wooin
Format:	Artikel
Sprache:	eng
Schlagworte:	albumins breast neoplasms cytotoxicity drugs mice myeloma nanocrystals neoplasm cells patients proteasome inhibitors solubility therapeutics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!